Patent Layout Of Antibody Drug Industry Leaders And Development Trends Of Antibody Drugs

Antibody drug is one of the fastest developing,most widely used and most promising drugs in modern biological pharmaceutical industry.With the development of biomedicine technology,antibody drugs begin to develop from mouse original to humanization,and a variety of new antibody technologies keep emerging,making antibody drugs rapidly improve their status in disease prevention and treatment.Compared with traditional chemical drugs and traditional Chinese medicines,antibody drugs have many advantages,such as high targeting,strong specificity and remarkable therapeutic effect,so they are widely used in the fields of tumor,autoimmune diseases and infectious diseases.As the leading enterprises in the antibody drug industry,Amgen and Roche have been making rapid technological innovations in the development of antibody drugs,representing and leading the development and growth of global antibody drugs.With the rapid development of the antibody drug industry and the particularity of its own innovation,its intellectual property protection plays an extremely important role.This paper intends to search and analyze the patents related to antibody drugs of leading enterprises in the domestic and foreign anti-antibody drug industry,to understand the current situation of patent distribution of leading enterprises in the domestic and foreign anti-antibody drug industry,and to find out the research hotspots and development gaps between domestic and foreign anti-antibody drugs,so as to provide the development status and development of anti-antibody drugs for the domestic anti-antibody drug industry from the perspective of patent protection.Developing trend,development opportunities,potential market of products,technical barriers and other information will promote domestic enterprises to enhance the use and application of intellectual property information,guide domestic enterprises to innovate and develop antibody drugs,and do a good job in patent evasion and intellectual property protection,so as to promote the vigorous development of domestic antibody drug industry.Research findings:(1)The research and development of traditional targets is still very hot: CD20,EGFR,VEGF and HER2 still occupy the majority of the antibody drug market.For these targets,Roche and Anjin have carried out in-depth patent distribution.(2)Antibody drugs targeting new targets are increasingly diverse: Sclerostin,IL-23,PCSK9,alpha 4beta 7 and IL-17 are being fully tapped;Immune checkpoint antibody drugs represented by pd-1 /L1 and ctla-4 are gaining momentum.In the future,research and patent protection on immune co-stimulators such as OX40,4-ibb,TIGR and GITR,as well as co-suppressors such as LAG3,tim-3,TIGIT and GAL9 will continue to increase.;Meanwhile,the following emerging targets should not be ignored: Factor D,gpc-3,-amyloid protein,HER3,DR5,c-met,ang-2,FcRH5,TAU,csf-1r,IGF,FGF,NGF and TGF-,etc.(3)Indications for antibody drugs will also continue to expand: the research and development of tumors and autoimmune diseases will continue to gain popularity,while the research and development of cardiovascular diseases such as hyperglycemia,atherosclerosis,psoriasis,asthma and rare diseases will gain popularity.(4)The research and development of new antibody structures,such as bispecific antibody drugs and conjugates of antibody drugs,has continued to increase.(5)With the discovery of biomarkers in various diseases,it will be a new direction for the choice of effective treatment of antibody drugs.In the future,subdividing patients,risk stratification and personalized treatment will be the new direction of development.(6)Guojian Pharmaceutical,a domestic anti-body drug company,has carried out technical follow-up and patent protection on traditional targets such as CD20,TNF-? and VEGF,and has also developed bispecific antibodies such as HGF/VEGF and VEGF/PIGF.(7)Hengrui Pharmaceutical,a domestic anti-body pharmaceutical enterprise,has great potential in the development of anti-PD-1 antibody,anti-PD-L1/TGF-?RII and other bispecific antibodies and anti-drug conjugates.Hengrui Medicine has applied for more patents and protected GITR,TIM-3,CD27,LAG-3 and other immune checkpoints.Hengrui Medicine is expected to occupy an advantageous position in the target of cancer immunity in the future.At present,China's antibody drug industry has just entered the initial stage of development.Although the innovation of antibody drugs and the number of products on the market have increased year by year,there are still large gaps in technology innovation and patent protection compared with the major international biotechnology countries.Fortunately,we can see that in addition to following the footsteps of international antibody drug giants,domestic enterprises are also actively carrying out independent innovation.In summary,Amgen and Roche,as the leading companies in the antibody drug industry,have conducted in-depth patent layout for their antibody drugs,which represents the research hotspot and development direction of antibody drugs.There is a big gap between domestic antibody drug companies and foreign leading companies in patent protection and technology innovation,but there is a large space for development.Keeping up with the development trend of antibody drugs,developing antibody drugs with international leading level and constructing a strict patent protection network are major challenges facing the domestic antibody drug industry.